Avita Medical, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
AVITA Medical reports an 11% revenue increase to $71.6 million in 2025, refinances its debt with a new $60 million credit facility, and expands its acute wound care product portfolio with new regulatory approvals and clinical studies.
NASDAQ
AVITA Medical's 2024 10-K filing reveals a 28% increase in total revenue driven by deeper market penetration and new product offerings, alongside strategic efforts to achieve profitability and expand global reach.
NASDAQ
Avita Medical secures a waiver and amendment to its credit agreement, files its annual report on Form 10-K, and provides updates on its product pipeline and financial performance.